Intelligence / Healthtech / New Clinical Trials / Novo Nordisk A/S
Novo Nordisk A/S
12 Nov 2026: Trial registered · AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 12 Nov 2026
- Title
- AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both
- Conditions
- Type 2 Diabetes
- Phase
- Phase 3
- Study Type
- Interventional
- Status
- Not Yet Recruiting
- Countries
- United States, Argentina, Australia, Brazil, Bulgaria, Canada, Croatia, Czechia, Denmark, Germany, Greece, Hungary, Israel, Italy, Poland, Portugal, Puerto Rico, Romania, Saudi Arabia, Slovakia, Spain, United Kingdom
- Country
- United States
- Reference
- NCT07931573
- Location
- United States, Argentina, Australia
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Find the decision makers at Novo Nordisk A/S
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Across AOS Research
Other records for Novo Nordisk A/S in our registers.
More from United States
New Clinical Trials
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.